In summary, our findings demonstrate that BCL-2 is a direct target of the rearranged MLL in ALL cells, translating into BCL-2 dependence and vulnerability to selective, on-target BCL-2 inhibition by the clinically active agent ABT-199. The gene discussed is KMT2A; the disease is acute lymphoblastic leukemia.